An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 10, Issue 3, 2011, Pages 171-177

  Cohn, Allen L ^a   Shumaker, Grace C ^b   Khandelwal, Pankaj ^c   Smith, David A ^d   Neubauer, Marcus A ^e   Mehta, Nilesh ^f   Richards, Donald ^g   Watkins, David L ^h   Zhang, Kathy ⁱ   Yassine, Mohamed R ⁱ  

^a Rocky Mountain Cancer Center   (United States)

^b Jackson Oncology Associates   (United States)

^c The West Cancer Center   (United States)

^d Northwest Cancer Specialists   (United States)

^e Kansas City Cancer Center   (United States)

^f Oncology Hematology Associates of Northern Illinois Ltd   (United States)

^g TEXAS ONCOLOGY   (United States)

^h USO Allison Cancer Center   (United States)

ⁱ AMGEN INC   (United States)

Author keywords

Colorectal neoplasm; FOLFIRI protocol; KRAS protein; Panitumumab

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MAGNESIUM; OXALIPLATIN; PANITUMUMAB;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; COLORECTAL CANCER; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HYPOMAGNESEMIA; INOPERABLE CANCER; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MUCOSA INFLAMMATION; NEUTROPENIA; ONCOGENE K RAS; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

EID: 80052435936     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2011.03.022     Document Type: Article

References (14)

1. E. Van Cutsem, M. Peeters, and S. Siena Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 25 2007 1658 1664 (Pubitemid 46797944)
2. ® (panitumumab) prescribing information 2010 Amgen Inc http://www.amgen.com/medpro/products-vectibix.html
3. R.G. Amado, M. Wolf, and M. Peeters Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 2008 1626 1634
4. D.J. Freeman, T. Juan, and M. Reiner Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone Clin Colorectal Cancer 7 2008 184 190 (Pubitemid 351758148)
5. S. Benvenuti, A. Sartore-Bianchi, and F. Di Nicolantonio Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies Cancer Res 67 2007 2643 2648 (Pubitemid 46548951)
6. M. Peeters, T.J. Price, and A. Cervantes Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer J Clin Oncol 28 2010 4706 4713
7. A.F. Sobrero, J. Maurel, and L. Fehrenbacher EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer J Clin Oncol 26 2008 2311 2319
8. A.D. Siddiqui, and B. Piperdi KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy Ann Surg Oncol 17 2010 1768 1776
9. M. Mabro, C. Louvet, and T. Andre Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer Am J Clin Oncol 26 2003 254 258 (Pubitemid 36712638)
10. M. Mabro, P. Artru, and T. Andre A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients Br J Cancer 94 2006 1287 1292
11. F.C. Bidard, C. Tournigand, and T. Andre Efficacy of FOLFIRI-3 (irinotecan D1, D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study Ann Oncol 20 2009 1042 1047
12. C. Tournigand, T. Andre, and E. Achille FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2003 229 237
13. M.E. Lacouture, E.P. Mitchell, and B. Piperdi Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer J Clin Oncol 28 2010 1351 1357
14. M. Fakih Management of anti-EGFR-targeting monoclonal antibody-induced hypomagnesemia Oncology 22 2008 74 76 (Williston Park) (Pubitemid 351224295)